Alma Therapeutics

Company Overview

Snapshot

Founded in February 2017 by Oz Cabiri, Alma Therapeutics operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing its novel drug delivery platform. In February 2026, Alma announced a key collaboration with Universkin to introduce an FDA-listed daily mineral serum SPF 50, marking a significant product development milestone.

Business overview

Alma Therapeutics is a Health Tech & Life Sciences company specializing in Pharma & Medical Biotechnology and Drug Delivery. The company is developing the Mobius Capsule, a novel drug delivery platform designed for the oral administration of complex and biologic molecules such as peptides, proteins, and antibodies. This technology utilizes a microneedle-array approach, offering a needle-free alternative to injectable drugs to enhance the quality of life for patients requiring chronic administration of such medications. Alma Therapeutics serves the Life Sciences and Healthcare sectors, targeting pharmaceuticals and patients globally.

Strategic signal

In February 2026, Alma Therapeutics, in collaboration with Universkin, introduced an FDA-listed daily mineral serum SPF 50. This development signals Alma's strategic expansion beyond its core drug delivery platform into adjacent markets, leveraging its expertise in medical technologies. For investors, this indicates a potential for diversified revenue streams and broader market penetration, validating the company's capability to bring new products to market.

Company Intelligence Q&A

What is Alma Therapeutics' primary focus?

Alma Therapeutics is focused on developing a capsule for the oral delivery of complex and biologic molecules, aiming to provide a needle-free alternative to injectable drugs.

What is the Mobius Capsule?

The Mobius Capsule is Alma Therapeutics' novel drug delivery platform designed for the oral administration of complex molecules and biologics, including peptides, proteins, and antibodies.

What significant product launch did Alma Therapeutics announce in February 2026?

In February 2026, Alma Therapeutics, in partnership with Universkin, announced the introduction of an FDA-listed daily mineral serum SPF 50 for post-procedure skincare.

Did Alma Therapeutics have a leadership transition in December 2025?

In December 2025, Alma announced a leadership transition where Lior Dayan was appointed Chairman of Sisram Medical, following eight years as CEO.

What strategic initiative did Alma Therapeutics unveil in April 2026?

In April 2026, Alma Therapeutics unveiled its longevity approach at its global Alma Academy, focusing on advancing long-term skin performance.